Dasheng Tian
Research Subjects
Dasheng Tian has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Erxu Tao1 shared publication
- Fei Huang
Department of orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China; Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
1 shared publication - Min Wang
School of Biomedical Engineering, Anhui Medical University, Hefei, 230032, China
1 shared publication - Sihai Li1 shared publication
- Tao Wang
Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
1 shared publication - Xianwen Wang
Anhui Medical University
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 64-80
Copper phosphate nanozymes combat implant-related infections by inducing cuproptosis-like death and inhibiting the two-component system
Implant-related infections, characterized by recalcitrant biofilm formation, antibiotic resistance, and immune evasion, pose a severe clinical burden in orthopedics due to the limited therapeutic efficacy of conventional approaches. Addressing this challenge requires innovative strategies capable of simultaneously disrupting biofilms and overcoming bacterial defense mechanisms. To address this, we developed flower-like copper phosphate (CuP) nanozymes with dual enzymatic activities (peroxidase- and glutathione peroxidase-like) that synergistically eradicate biofilms for implant-related infections through cuproptosis-like death and two-component system (TCS) inhibition. In vitro antimicrobial experiments demonstrated that CuP nanozymes significantly inhibited and disrupted bacterial biofilms. These CuP nanozymes generate reactive oxygen species (ROS) while depleting glutathione (GSH), disrupting bacterial membranes, and disrupting metabolic processes such as the TCA cycle and glycolysis. Transcriptomic analysis revealed suppressed expression of oxidative phosphorylation genes and quorum-sensing regulators, confirming dual targeting of bacterial viability and communication. In vivo, CuP nanozymes effectively eliminated biofilm infections on implants, reduced inflammatory responses, and demonstrated excellent biocompatibility. By integrating enzymatic ROS amplification, metabolic interference, and TCS inhibition, this strategy offers a transformative approach to combat resistant implant infections, surpassing conventional therapies in both efficacy and safety.
- 1 August 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 64-80
Open AccessCopper phosphate nanozymes combat implant-related infections by inducing cuproptosis-like death and inhibiting the two-component system
Implant-related infections, characterized by recalcitrant biofilm formation, antibiotic resistance, and immune evasion, pose a severe clinical burden in orthopedics due to the limited therapeutic efficacy of conventional approaches. Addressing this challenge requires innovative strategies capable of simultaneously disrupting biofilms and overcoming bacterial defense mechanisms. To address this, we developed flower-like copper phosphate (CuP) nanozymes with dual enzymatic activities (peroxidase- and glutathione peroxidase-like) that synergistically eradicate biofilms for implant-related infections through cuproptosis-like death and two-component system (TCS) inhibition. In vitro antimicrobial experiments demonstrated that CuP nanozymes significantly inhibited and disrupted bacterial biofilms. These CuP nanozymes generate reactive oxygen species (ROS) while depleting glutathione (GSH), disrupting bacterial membranes, and disrupting metabolic processes such as the TCA cycle and glycolysis. Transcriptomic analysis revealed suppressed expression of oxidative phosphorylation genes and quorum-sensing regulators, confirming dual targeting of bacterial viability and communication. In vivo, CuP nanozymes effectively eliminated biofilm infections on implants, reduced inflammatory responses, and demonstrated excellent biocompatibility. By integrating enzymatic ROS amplification, metabolic interference, and TCS inhibition, this strategy offers a transformative approach to combat resistant implant infections, surpassing conventional therapies in both efficacy and safety.